Thrombocytosis in malignant pleural mesothelioma

Area of Science:

• Oncology
• Hematology
• Pathology

Background:

• Thrombocytosis, a condition of elevated platelet count, is observed in various cancers.
• Malignant pleural mesothelioma and non-small cell lung carcinoma are distinct thoracic malignancies with potential overlapping clinical features.

Purpose of the Study:

• To compare the prevalence of thrombocytosis and thromboembolism in patients with malignant pleural mesothelioma versus non-small cell lung carcinoma.
• To investigate factors influencing thrombocytosis within the malignant pleural mesothelioma cohort.

Main Methods:

• Retrospective analysis of 41 patients with malignant pleural mesothelioma and 40 patients with non-small cell lung carcinoma.
• Platelet counts and thromboembolism events were assessed from necropsy examinations.
• Statistical comparisons were performed between patient groups and within the mesothelioma cohort based on histology and age.

Main Results:

• Thrombocytosis was significantly more prevalent in malignant pleural mesothelioma patients (56.8%) compared to non-small cell lung carcinoma patients (24.2%).
• The prevalence of thromboembolism was comparable between the two cancer groups.
• Within the mesothelioma group, thrombocytosis varied by histological subtype (76.9% in mixed, 57.1% in epithelial, 30% in sarcomatous) and was more common in patients under 70 years old.

Conclusions:

• Malignant pleural mesothelioma is associated with a higher incidence of thrombocytosis compared to non-small cell lung carcinoma.
• Histological type and patient age are significant factors associated with thrombocytosis in malignant pleural mesothelioma.
• While thrombocytosis is more frequent in mesothelioma, thromboembolism rates do not significantly differ between these two malignancies.